Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1513 clinical trials
Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction (SAVED-1)

(experimental intervention) in severe emphysema/COPD patients with failed bronchoscopic lung volume reduction (BLVR) via the use of endobronchial valves (EBVs) therapy. In select patients, the lung fissure

  • 0 views
  • 14 Mar, 2022
  • 1 location
Prospective Multicentric Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate Cyclophosphamide) in Large Granular Lymphocytes Leukemia

LGL leukemia represents a rare subtype of chronic T or NK lymphoproliferative disorders. It is an indolent disease, the main hematological or autoimmune complications lead to a treatment in more

  • 35 views
  • 05 Sep, 2021
  • 65 locations
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas

lymphoma
  • 0 views
  • 15 Mar, 2022
  • 20 locations
Routine Cardiac Screening in Sarcoidosis Patients (PAPLAND)

This protocol is an unblended randomized screening trial will have consecutive patients with no suggestion of cardiac sarcoidosis according to usual screening enroll in an enhanced screening protocol. The routine clinical care is to gather patient's history of symptoms and under go an ECG. If a patient has an abnormal …

cardiac sarcoidosis
  • 207 views
  • 15 Feb, 2022
  • 5 locations
A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous …

platelet count
neutrophil count
immunohistochemistry
blood disorder
immunoglobulin
  • 41 views
  • 09 Apr, 2022
  • 62 locations
A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous …

platelet count
neutrophil count
immunohistochemistry
blood disorder
immunoglobulin
  • 32 views
  • 06 Apr, 2022
  • 64 locations
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis

This is an open-label, multicenter, Phase 2 study in subjects with previously treated patients with light chain (AL) amyloidosis in need for therapy. Approximately 35 subjects will receive therapy with belantamab mafodotin. Subject participation will include a Screening Phase, a Treatment Phase, a Post-Treatment Observation Phase, and a Long-term Follow-up …

  • 0 views
  • 13 Mar, 2021
  • 5 locations
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1), in subjects with MM having progressed within one 18 months of initial treatment including autologous stem cell transplantation (ASCT) (Cohort 2a), and without …

refractory multiple myeloma
serum proteins
maintenance therapy
electrophoresis
proteasome inhibitor
  • 12 views
  • 09 Sep, 2021
  • 27 locations
First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma

The primary objectives of the study are: In the phase 1 portion of the study: To assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5458 as monotherapy in patients with relapsed or refractory multiple myeloma (MM). In the phase …

refractory multiple myeloma
immunotherapeutic agent
proteasome inhibitor
lenalidomide
immunomodulatory imide drug
  • 24 views
  • 08 Apr, 2022
  • 20 locations
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with …

refractory multiple myeloma
proteasome inhibitor
measurable disease
monoclonal antibodies
cancer
  • 15 views
  • 07 Apr, 2022
  • 37 locations